SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 7, 2007
Savient Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
| | | | | |
| Delaware | | 0-15313 | | 13-3033811 |
| |
| (State or other juris- | | (Commission | | (IRS Employer |
| diction of incorporation | | File Number) | | Identification No.) |
| | | |
| One Tower Center, 14th Floor |
| East Brunswick, New Jersey 08816 |
| |
| (Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code: (732) 418-9300
| | | |
| Not applicable |
| |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 2.02. Results of Operations and Financial Condition
On May 7, 2007, Savient Pharmaceuticals, Inc. (the “Registrant”) announced its financial results for the quarter ended March 31, 2007. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In addition, on May 8, 2007, the Registrant held a publicly available live webcast discussion of its financial results for the quarter ended March 31, 2007. The transcript of the May 8, 2007 conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | SAVIENT PHARMACEUTICALS, INC.
| |
| Date: May 11, 2007 | By: | /s/ Philip K. Yachmetz | |
| | | Philip K. Yachmetz | |
| | | Executive Vice President &
Chief Business Officer | |
| |
EXHIBIT INDEX
| | | |
| Exhibit No. | | Description |
| |
| 99.1 | | Press release dated May 7, 2007 |
| | | |
| 99.2 | | Transcript dated May 8, 2007 |
